Overview

The Gene Technology Act 2004 was enacted to regulate the handling, use, and potential environmental release of genetically modified organisms (GMOs) in Australia, aiming to protect human health and the environment. This Act established the framework for the oversight of GMOs, including the assessment of risks associated with their release and the implementation of risk management strategies. The Office of the Gene Technology Regulator (OGTR) was created as part of this legislative framework to administer and enforce the provisions of the Act. The policy objective of the Act is to ensure that GMOs are managed in a way that minimises any potential risks to human health and the environment, while promoting the safe and beneficial use of genetic technologies. The Act provides a comprehensive system for the assessment and regulation of GMOs, including the requirement for risk assessments and management plans for products like the proposed live attenuated vaccine for dogs.

Scope and Application

The invitation to comment on the commercial release of Nobivac Puppy DP Plus, a live attenuated vaccine containing canine distemper virus and a genetically modified canine parvovirus, pertains to Intervet Australia Pty Ltd's application for approval from the Office of the Gene Technology Regulator (OGTR) and the Australian Pesticides and Veterinary Medicines Authority (APVMA). This application is specific to the use of the vaccine as a prescription-only product for dogs in Australia, highlighting the necessity for dual regulatory approval to ensure compliance with both gene technology and veterinary medicine regulations. The OGTR has developed a Risk Assessment and Risk Management Plan (RARMP) to evaluate potential risks to human and animal health and the environment associated with the import, transport, storage, and disposal of the vaccine. The public is invited to review the RARMP and provide submissions on any identified risks by 19 June 2024. These submissions are integral to the decision-making process regarding the issuance of the necessary licence for commercial supply in Australia. Further information and the RARMP can be accessed via the OGTR website or through direct contact with the Office of the Gene Technology Regulator.

Key Provisions

The main sections of the legislation (C2024G00254) involve the assessment of the application for the commercial release of a new veterinary vaccine, Nobivac Puppy DP Plus, by the Office of the Gene Technology Regulator (OGTR). Section 2 requires Intervet Australia Pty Ltd to seek approval from both the OGTR and the Australian Pesticides and Veterinary Medicines Authority (APVMA) before the vaccine can be used in Australia. This dual approval process ensures that the vaccine meets both genetic modification safety and veterinary medicine standards. The OGTR has prepared a Risk Assessment and Risk Management Plan (RARMP) to evaluate the potential risks to human and animal health and the environment associated with the vaccine. Section 3 invites written submissions from the public regarding the RARMP, inviting comments on the assessment before a decision is made on whether to issue the licence. The deadline for submissions is 19 June 2024, and they should reference DIR 202. The obligations imposed on Intervet Australia Pty Ltd and the OGTR by this legislation are significant. For Intervet Australia Pty Ltd, the primary obligation is to seek and obtain necessary approvals from both the OGTR and the APVMA before the vaccine can be supplied commercially in Australia. This involves providing comprehensive data and documentation, including the RARMP, to support the safety and efficacy of the vaccine. The OGTR, on the other hand, is tasked with reviewing the RARMP, assessing the potential risks, and facilitating public consultation by inviting submissions on the assessment. The Regulator must ensure that all submissions are considered before making a decision on whether to issue the licence. Breaches of the provisions of this legislation can result in serious consequences. Although specific offences and penalties are not detailed in the text, it can be inferred that failure to comply with the regulatory requirements for obtaining the necessary approvals, or misrepresenting information in the application, could lead to legal action. For Intervet Australia Pty Ltd, non-compliance could result in the refusal to issue the licence, preventing the commercial release of the vaccine. For the OGTR, failure to properly assess the risks and make an informed decision could lead to regulatory oversight and potential legal repercussions. The exact penalties for such breaches would depend on the specific nature of the non-compliance and would likely be determined by the relevant authorities.